You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 2, February 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, SAN FRANCISCO, CALIF, MAY 21 TO MAY 24, 1989-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Use of Fine-Needle Aspirates of Breast Cancers to Evaluate Hormone-Receptor Status

Joel Lundy, MD; Mary Lozowski, MS; Darya Sadri, MS; Yousri Mishriki, MD

Arch Surg. 1990;125(2):174-176.


Abstract

• The objective of this study was to determine the reliability of immunocytochemical assays of hormone receptors using specimens obtained by fine-needle aspiration of breast cancers. A peroxidase-antiperoxidase immunocytochemical assay was used on 96 aspirates from 47 patients to determine estrogen and progesterone receptor status. Of 27 estrogen receptor–positive cases by steroid-binding analysis, 25 were positive by immunocytochemical assay. Of 21 estrogen receptor–negative cases, 17 were negative by immunocytochemical assay. Of 21 progesterone receptor–positive cases 19 were positive by immunocytochemical assay. Of 27 progesterone receptor–negative cases 25 were negative by immunocytochemical assay. An additional 11 small tumors were evaluated by immunocytochemical assay alone and results were interpretable based on our prior data. With the caveat that a cellular aspirate is obtained, immunocytochemical assay can distinguish hormone receptor–negative and hormone receptor–positive tumors and can be used to assay tumors too small for standard steroid-binding analysis.

(Arch Surg. 1990;125:174-176)



Author Affiliations

From the Department of Surgery, State University of New York–Health Science Center, Stony Brook (Dr Lundy); the Surgical Oncology Laboratory (Dr Lundy and Ms Sadri) and the Department of Pathology (Ms Lozowski and Dr Mishriki), Winthrop-University Hospital, Mineola, NY.


Footnotes

Accepted for publication November 9, 1989.

Read before the annual meeting of the Society of Surgical Oncology, San Francisco, Calif, May 21, 1989.

Reprint requests to 222 Station Plaza N, Suite 603, Mineola, NY 11501 (Dr Lundy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.